Literature DB >> 26363097

Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.

Ting Shuang1, Min Wang2, Cong Shi1, Yingying Zhou1, Dandan Wang1.   

Abstract

MiR-134 has been reported to have a role in the development and progression of various cancers. In this study, we found that miR-134 expression was significantly decreased in chemo-resistant serous epithelial ovarian cancer (EOC) patients. Over-expression of miR-134 enhanced the sensitivity of SKOV3-TR30 cells to paclitaxel, and increased paclitaxel-induced apoptosis. Further, Pak2 was identified as a direct target of miR-134, and Pak2-specific siRNA increased cell inhibition rate and promoted paclitaxal-induced apoptosis. By regulating Pak2 expression, miR-134 could mediate Bad phosphorylation at Ser112 and Ser136, which affected cell survival and apoptosis. In conclusion, our findings indicate that repression of miR-134 and consequent up-regulation of Pak2 might contribute to paclitaxel resistance.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Drug resistance; Ovarian cancer; Paclitaxel resistance; Pak2 gene; miR-134 expression

Mesh:

Substances:

Year:  2015        PMID: 26363097     DOI: 10.1016/j.febslet.2015.08.047

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

1.  PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma.

Authors:  Wei-Wei Deng; Lei Wu; Lin-Lin Bu; Jian-Feng Liu; Yi-Cun Li; Si-Rui Ma; Guang-Tao Yu; Liang Mao; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

Review 2.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

3.  Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.

Authors:  Zibi Marchocki; Alicia Tone; Carl Virtanen; Richard de Borja; Blaise Clarke; Theodore Brown; Taymaa May
Journal:  J Ovarian Res       Date:  2022-05-02       Impact factor: 5.506

4.  miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.

Authors:  Zhenhua Hu; Mingbo Cai; Ying Zhang; Lingling Tao; Ruixia Guo
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

5.  Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1.

Authors:  Cheng-Cao Sun; Shu-Jun Li; De-Jia Li
Journal:  Oncotarget       Date:  2016-06-14

6.  Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis.

Authors:  Ferah Budak; Salih Haldun Bal; Gulcin Tezcan; Halis Akalın; Guher Goral; Haluk Barbaros Oral
Journal:  J Immunol Res       Date:  2016-09-19       Impact factor: 4.818

7.  MicroRNA-519a inhibits the proliferation and promotes the apoptosis of ovarian cancer cells through targeting signal transducer and activator of transcription 3.

Authors:  Fei Tian; Ligang Jia; Zhaoping Chu; Hua Han; Yuan Zhang; Jianhui Cai
Journal:  Exp Ther Med       Date:  2017-12-06       Impact factor: 2.447

8.  MicroRNA miR-4779 suppresses tumor growth by inducing apoptosis and cell cycle arrest through direct targeting of PAK2 and CCND3.

Authors:  Kyung Hee Koo; Heechung Kwon
Journal:  Cell Death Dis       Date:  2018-01-23       Impact factor: 8.469

9.  NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.

Authors:  Ting Shuang; Min Wang; Yingying Zhou; Cong Shi; Dandan Wang
Journal:  Oncotarget       Date:  2017-04-11

10.  The Fra-1-miR-134-SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells.

Authors:  Jianmin Wu; Yimin Sun; Pei-Ying Zhang; Mengyao Qian; Hengchao Zhang; Xiao Chen; Di Ma; Yunsheng Xu; Xiaoming Chen; Kai-Fu Tang
Journal:  Cell Death Dis       Date:  2016-09-29       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.